Changes Ahead For Pfizer, But Don't Expect A "Big Bang," Read Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer turns in flat first-quarter sales and keeps investors waiting for more details on plans for potential spinouts or restructuring.
You may also be interested in...
Are Emerging Markets Part Of Big Pharma's Core Business?
As Big Pharma companies increasingly look to emerging markets to capture some of the growth lost from the patent cliff in the U.S. and Europe, they are also shifting focus more to branded generics, leaving some investors to question whether companies would be better off spinning out their emerging market units, which would leave behind smaller companies focused on the core business of developing and marketing innovative therapies
Death Scare For Pfizer's Pipeline Star Tofacitinib May Be Just A Storm In a Teacup
Mortality rate for Pfizer's oral RA drug tofacitinib is similar to what's been seen with established TNF blockers, which have labels warning of potential for death by infection and cancer.
Freed From Pfizer, Capsugel May Find More Market Opportunities
Deal heightens attention Pfizer is attracting from the investment community, already anticipating divestments outside the firm's innovative core pharma business.